Osteoporosis Sunlight Omnisense 9000 Granted CE Mark

Osteoporosis Sunlight Omnisense 9000 Granted CE Mark

Osteoporosis Sunlight Omnisense 9000 Granted CE Mark, Petah Tikva, Israel – June 2014. BeamMed, a leading provider of bone health-related measurement systems, today announced that it has received CE Mark to its new Sunlight Omnisense™ 9000 Quantitative Ultrasound Bone Sonometer.

The new Sunlight Omnisense 9000 is based on proprietary Sunlight Omnipath™ quantitative ultrasound technology, which has been proven in thousands of installations worldwide to deliver highly accurate and safe multi-site assessment of bone status. A standalone device designed for use in any clinic or physician office, Sunlight Omnisense 9000 is ideal for managing and monitoring osteoporosis diagnosis and treatment for any patient. It uses different software modules and five ethnical clinical reference databases, making it suitable for patients aged 0-99 years.

The new version of Sunlight Omnisense 9000 is designed for ultimate ease of use and versatility. The advanced hardware platform features a large, 19” touch-screen, enabling fast and convenient operation. The new-generation software improves versatility and performance, offering a choice of operation modes. With its newly designed interface, the Sunlight Omnisense 9000 is exceptionally easy to learn and use.

Having gained CE Mark, Sunlight Omnisense 9000 is now available in Europe and in other international markets.

 For more information, please contact info@beammed.com

Beammed Osteoporosis Sunlight Omnisense 9000

Beammed develops manufacture and market monitoring solutions for bone density assessments. We are leaders in advanced ultrasound technology and devices that enable physicians to provide early assessment, diagnosis, and monitoring of osteoporosis and bone age. Thousands of our devices are in use in physician offices, clinics, HMO’s, hospitals, research centers, check-up centers and pharmacies around the world.

Beammed bone density assessment patented devices is based on our Omnipath™ axial transmission technology. This is a quantitative ultrasound technology that has an effective screening tool for osteoporosis which improves HEDIS measures. It allows reaching 5-stars rating for Hedis OMW. Measurement using our Omnisense and MiniOmni is reimbursed in the USA and other countries.

Leave a reply